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First wave of the influenza A/H1N1v pandemic in Switzerland
Abstract
AIM: To describe the disease burden, clinical pattern and outcome of influenza-related cases presenting
to a Swiss Emergency Department (ED), during the first wave of the 2009 pandemic. METHODS:
Retrospective analysis of prospectively collected data at the University Hospital of Basel, Switzerland.
All patients presenting to the ED with influenza-like symptoms from June 1 to October 23, 2009, were
studied. Rate of hospitalisation, demographic characteristics, symptoms, microbiological diagnoses and
complications of influenza infection were analysed. RESULTS: One tenth (808 of 8356 patients) of all
non-trauma ED presentations, during the study period, were a result of suspected influenza-related
illness. Influenza A/H1N1v infection accounted for 5% of these presentations. Patients aged 50 years or
less accounted for 87% of these presentations and for 100% of A/H1N1v infection. The highest
detection rate of A/H1N1v-infection occurred in July, and the highest rate of clinical presentations
occurred in August 2009. Underlying medical disease was observed in 14% of all patients. The presence
of fever, cough and myalgia was the prime clinical predictor for the presence of A/H1N1v infection.
16% of patients with this triad suffered from A/H1N1v. CONCLUSION: Suspected A/H1N1v infection
contributed to a considerable health care burden in Switzerland. However, the rate of true positivity was
low (5%), hospitalisations rare (5%), and mortality did not occur. Therefore, the first wave of the
A/H1N1v pandemic in Switzerland was rather media "hype" than real threat.
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Summary
Aim: To describe the disease burden, clinical
pattern and outcome of influenza-related cases
presenting to a Swiss Emergency Department
(ED), during the first wave of the 2009 pandemic.
Methods: Retrospective analysis of prospec-
tively collected data at the University Hospital of
Basel, Switzerland. All patients presenting to the
ED with influenza-like symptoms from June 1 to
October 23, 2009, were studied. Rate of hospitali-
sation, demographic characteristics, symptoms,
microbiological diagnoses and complications of
influenza infection were analysed.
Results:One tenth (808 of 8356 patients) of all
non-trauma ED presentations, during the study
period, were a result of suspected influenza-re-
lated illness. Influenza A/H1N1v infection ac-
counted for 5% of these presentations. Patients
aged 50 years or less accounted for 87% of these
presentations and for 100% of A/H1N1v infec-
tion.
The highest detection rate of A/H1N1v-in-
fection occurred in July, and the highest rate of
clinical presentations occurred in August 2009.
Underlying medical disease was observed in 14%
of all patients. The presence of fever, cough and
myalgia was the prime clinical predictor for the
presence of A/H1N1v infection. 16% of patients
with this triad suffered from A/H1N1v.
Conclusion: Suspected A/H1N1v infection
contributed to a considerable health care burden
in Switzerland. However, the rate of true positiv-
ity was low (5%), hospitalisations rare (5%), and
mortality did not occur. Therefore, the first wave
of the A/H1N1v pandemic in Switzerland was
rather media “hype” than real threat.
Key words: A/H1N1v; comorbidities; PCR testing;
risk; Oseltamivir; pandemic
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Introduction
In April 2009, a novel influenza A/H1N1 virus
was detected in two specimens independently col-
lected in Southern California, and was subse-
quently recognized to be the cause of an outbreak
of respiratory disease in Mexico that had been on-
going since February [1, 2]. This new influenza A
strain is a result of genome reassortment with
segments found in porcine, avian, and human in-
fluenza [3]. It is currently spreading in humans,
giving rise to the first pandemic in 40 years, as de-
fined by the criteria of theWorld Health Organi-
zation (WHO). It represents the first influenza A
virus pandemic since the emergence of H3N2
(Hong Kong Flu) in 1968. It is believed that the
pandemic H1N1/09 virus, such as other influenza
A viruses, is transmitted from infected individuals
through droplets by coughs or sneezes, creating
virus-containing aerosols [4]. Its transmissibility is
thought to be equal or higher to that known from
seasonal influenza [5]. The incubation time of in-
fluenza A has been estimated to range between 1
and 4 days [6]. The novel H1N1/09 influenza
A virus has generally been affecting young and
middle-aged people, including pregnant women
who seem to be at an increased risk for complica-
tions from A/H1N1 virus infection, including a
higher estimated rate of hospital admission [7].
Furthermore, patients who are immuno-compro-
mised or who have chronic underlying diseases are
considered to be at high risk for influenza-related
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complications. There is recent evidence that an
IgG2 deficiency predisposes patients to an unfa-
vourable outcome due to A/H1N1v infection [8].
However, the case fatality rate appears to vary sig-
nificantly between countries [1, 9]. In a previous
study, severe illness resulting from A/H1N1v in-
fection among young, healthy persons was identi-
fied. The only variable that was significantly asso-
ciated with a positive outcome was the receipt of
antiviral drugs within 2 days after the onset of ill-
ness [10]. In Australia and New Zealand, several
Intensive Care Units (ICUs) had to provide me-
chanical ventilation for 201 patients from June to
August 2009 for A/H1N1v–associated respiratory
failure. Of those, approximately one third even re-
ceived extracorporeal membrane oxygenation
(ECMO).Mainly young patients suffered from se-
vere hypoxemia and had a mortality rate of 21% at
the end of the study period [11].
Media coverage of A/H1N1v has been consid-
erable, particularly when theWHO declared pan-
demic alert phases 4, 5 and 6.There are significant
regional differences in public perceptions of ill-
ness severity and risk of A/H1N1v infection [12].
An increase in anxiety can lead to behavioural
changes to the pandemic, such as reduced public
transport use, purchase of materials for self-pro-
tection, and can even result in shortages of medi-
cation, apart from a substantial economic impact,
deriving from the costs of prevention and treat-
ment, work absenteeism and hospitalisations.
Due to factors, such as extensive media cover-
age, flu clinics were established in many Emer-
gency Departments (ED), because of a suddenly
increasing number of, mainly, younger patients
presenting with flu-like symptoms. For reasons
regarding prevention of disease transmission, the
resources used for these flu clinics were consider-
able. The aim of the present study was to describe
the disease burden, clinical pattern and outcome
of influenza-related ED presentations, and finally
to discuss the usefulness and cost of widespread
polymerase chain reaction (PCR)-testing and flu
clinics during the first wave of the 2009A/H1N1v-
pandemic in Northwest Switzerland.
Methods
We prospectively included all patients presenting to
our ED with flu-like symptoms from June 1 to October
23, 2009. The study took place at the University Hospi-
tal of Basel, a 700-bed primary and tertiary care centre.
Over 41000 patients are seen in the ED every year. Pa-
tients with flu-like symptoms presenting to the ED were
evaluated in a specialised and separate flu clinic, after
triage in the ED according to the Emergency Severity
Index (ESI), extended by an additional protocol for
A/H1N1v infection [13]: ESI 3 patients received their
examination in the ED, ESI 4 patients were evaluated by
the flu clinic, and ESI 5 patients were triaged according to
the “see-and-treat” pathway, immediately discharged and
not further analysed. The flu clinic provided a 7-days-a-
week, 2-shift service of previously trained nurses and phy-
sicians during the entire study period. Standardised pro-
tocols for the identification of patients to be tested with
naso-pharyngeal swabs, and for patients to be treated with
oseltamivir, were introduced prior to the start of the study
period [13]. Briefly, patients meeting the WHO criteria,
modified by the Swiss Health Authorities (BAG), for A/
H1N1v infection were tested, and patients with risk fac-
tors for severe disease, and those with more severe symp-
toms were treated. It is noteworthy, that the case defini-
tion from the WHO changed during the study period.
This change was adapted by the BAG and introduced to
our ED on August 3, 2009, after personal information,
written instructions, and a change in ED protocols [13]
were implemented. Specifically, testing criteria before
August 3, were fever, respiratory symptoms, and a travel
history to high incidence countries (weekly changes by
the BAGwere followed).Testing criteria were changed on
August 3: patients with no fever, no high risk features, no
hospitalisation, no severe course of disease, no employ-
ment factors (hospital or school employees), no contact
to persons with high risk features, no contact to geriatric
or child care facilities, and finally no mass incidents (>3
suspected cases from one single institution, such as a
school) were not tested after August 3.
Study design
This study was a prospective, observational, mono-
centric cohort study of patients presenting to the ED of
the University Hospital Basel with flu-like symptoms.
The study was approved by the local ethics committee
(EKBB 311/09).
Data collection
A standardised IT-based form that included demo-
graphic data, underlying medical conditions, clinical
signs, symptoms, and treatment, was filled out by physi-
cians. Additional retrospective data on hospitalised pa-
tients were obtained by the Department of Infectious Dis-
eases. For A/H1N1v testing, a PCR-based diagnostic
NAT-testing specific for A/H1N1 was used, as previously
described [14, 15]. The robustness of the assay was
confirmed by bi-weekly comparison with A/H1N1v se-
quences available in the NCBI database.
Descriptive analyses were performed to summarise
the baseline characteristics of the study population. PCR
testing was done according to predefined criteria during
the surveillance period. From this approach, we obtained
an estimate of disease prevalence and its change over time.
The data were transferred into a Microsoft Excel 2007
spreadsheet and validated before being transferred into
the statistical analysis package SPSS software, version
15.0 for Windows. Categorical variables were compared
using chi-square and Fisher’s exact tests as appropriate.
A p-value of <0.05 (two-tailed) was considered to indicate
statistical significance.
Cost estimates were based on wages for one nurse
and one physician of average experience in our hospital,
working two daily shifts during the entire study period.
Additionally, the insurance reimbursement cost of $ 205
for oneA/H1N1v-PCR test was used without considering
costs for materials and transport.
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From June 1 to October 23, 2009, a total of
808 patients (10% of all non-trauma ED patients)
presented to the ED with flu-like symptoms, of
which 43 (5%) were tested positive for A/H1N1v.
Oseltamivir therapy was administered to 132 pa-
tients, of which 119 patients were tested negative.
The demographical data are summarised in
table 1. The median age of the patients was 32
years (Interquartile Range [IQR] 24, 34 years).
Fifty-two percent of the patients were female. 110
patients (14%) were considered at increased risk
for influenza-related complications on the basis of
age (≥65 years) or the presence of an underlying
medical condition. Among these 110 patients, 31
(4%) were 65 years of age or older; and 35 (4%)
had at least two such conditions. Similar to pa-
tients with seasonal influenza, asthma and chronic
obstructive pulmonary disease (COPD) were the
two most common comorbidities in the patients
we studied. Among the 110 patients of the high-
risk group, 90 patients were tested. Of these, only
4 patients were tested A/H1N1v–positive. Among
patients 65 years of age or older, 15 patients had
an underlying medical condition. However, no
patient older than 50 years was identified to be
A/H1N1v-positive. A total of 17 patients (2%)
were pregnant (see table 1), three of whom had an-
other underlying medical condition.
The median time from the onset of illness to
presentation was 2 days (IQR 2, 4). Table 2 shows
symptoms and vital signs of the study population.
Symptoms at presentation included a history of
fever in 426 (53%), coughing in 389 (48%), throat
pain in 432 (54%), myalgia in 400 (50%), head-
ache in 361 (45%), sneezing in 354 (44%), and
diarrhoea in 83 (10%) cases.
Vital signs were recorded (table 2). In very few
cases, they were markedly out of range.An oxygen
saturation rate below 95% was reported in 21
(4%) patients, a systolic blood pressure below 90
mmHg in 2 (1%), a heart rate greater than 90/min
in 222 (38%), and a respiratory rate of greater
than 20/min in 29 cases. Body temperature was re-
corded in 620 cases, and was higher than 38 de-
grees Celsius in 297 (48%) cases.
Risk factors (table 3) for positive A/H1N1v-
PCR testing were an age of 50 years or younger,
male sex, recent travel, initiation of Oseltamivir
therapy, a history of fever, a documented body
temperature of 38 degrees Celsius or higher,
coughing, myalgia and sneezing. The analysis of
the combinations of flu-like symptoms is shown in
figure 1. If fever, cough and myalgia were reported
by the patient, the likelihood of A/H1N1v positiv-
ity significantly increased to 16%.
Weekly presented cases were analysed and
compared: While the prevalence of A/H1N1v in-
fection was higher in July, the number of pre-
sented cases rapidly increased in August (figure 2).
Due to the fundamental change of testing
practise triggered by decisions of the WHO, our
cohort was separately analysed for the period be-
fore this change (June 1 to August 2) and the pe-
riod after this change (August 3 to October 23).
Results
Table 1
Demographics of ED
patients with ﬂu-like
symptoms.
All patients, No. 808
Age
Median age, y (IQR) 32 (24, 42)
Gender
Females, No. (%) 419 (52)
Travel, No. (%) 207 (26)
Spain/Portugal 64 (8)
USA/Canada 22 (3)
Great Britain 17 (2)
Other countries 104 (13)
Professional contact, No. (%)
$
163 (20)
Time to presentation, No. (%) 622 (77)
Median time (d), (IQR) 2 (1, 4)
PCR performed, No. (%) 521 (65)
Positive PCR 43 (5)
Initiation of Oseltamivir therapy, No. (%) 132 (16)
Patients at risk for unfavourable outcome, No. (%) 110 (14)
Age ≥65 y* 31 (4)
Chronic pulmonary disease* 24 (3)
Cardiovascular disease* 20 (2)
Diabetes mellitus* 20 (3)
Pregnancy* 17 (2)
Immunosuppression*
#
10 (1)
Patients with other medical condition 14 (2)
$
including health care providers and patients in education system
* several answers may apply
#
including solid organ, stem cell and bone marrow transplanta-
tion, HIV infection/AIDS and drug dependence
Table 2
Symptoms and vital
signs of ED patients
with ﬂu-like
symptoms.
Patients, total No. 808
History of fever, No. (%) 426 (53)
Cough, No. (%) 389 (48)
Throat pain, No. (%) 432 (54)
Myalgia, No. (%) 400 (50)
Headache, No. (%) 361 (45)
Sneezing, No. (%) 354 (44)
Diarrhea, No. % 83 (10)
Oxygen saturation (%)*, n = 522, Median (IQR) 98 (97, 99)
<95%, No. (%) 21 (4)
Systolic blood pressure (mm Hg)*,
n =568, Median (IQR)
125 (117, 140)
<90 mm Hg, No. (%) 2 (<1%)
Heart rate (f/min)*, n = 590, Median (IQR) 87 (76, 98)
>90/min, No. (%) 222 (38)
Temperature (°C)*, n = 620, Median (IQR) 37.8 (37.3, 38.6)
>38 °C, No. (%) 297 (48)
Respiratory rate (f/min)*, n = 327, Median (IQR) 12 (11, 16)
>20/min, No. (%) 29 (9)
* where data available
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While in the first period the proportion of positive
tests was 24%, it declined to 4% in the second pe-
riod. The test rates were comparable with 56%
and 67%.
Forty-two patients (5%) presenting to the ED
with ESI 3 were admitted to the hospital. None of
these patients were tested positive for A/H1N1v.
In order to compare the cohort of all 808 ED
patients with all hospitalised patients under suspi-
cion of A/H1N1v infection, we retrospectively
analysed the prevalence of A/H1N1v in the differ-
Table 3
Risk factors for positive A/H1N1v-PCR.
A/H1N1v-PCR + p-Value
Age (y) 13–50 (n = 699) 43 p = 0.002
51–90 (n = 109) 0
Gender Female (n = 419) 16
Male (n = 389) 27 p = 0.034
Travel Yes (n = 207) 33 p <0.001
No (n = 601) 10
Professional contact Yes (n = 163) 6 n.s.*
No (n = 645) 37
Initiation of Oseltamivir therapy Yes (n = 132) 13 p = 0.014
No (n = 676) 30
History of fever Yes (n = 426) 35 p <0.001
No (n = 382) 8
Temperature (n = 620)
#
≥38.0 °C (n = 297) 27 p = 0.031
<38.0 °C (n = 323) 16
Cough Yes (n = 389) 32 p <0.001
No (n = 419) 11
Throat pain Yes (n = 432) 25 n.s.*
No (n = 376) 18
Myalgia Yes (n = 400) 33 p <0.001
No (n = 408) 10
Headache Yes (n = 361) 24 n.s.*
No (n = 447) 19
Sneezing Yes (n = 354) 27 p = 0.008
No (n = 454) 16
Diarrhea Yes (n = 83) 6 n.s.*
No (n = 725) 37
* not significant;
#
where data available
Figure 1
Symptoms and
prediction of A/
H1N1v-positivity.
Neither Fever NOR
Temperature ≥38.0 °C
(n = 354)
20
16
12
8
4
0
%
p = 0.031
p <0.001
p <0.001
Fever AND
Temperature ≥38.0 °C
(n = 269)
Neither Fever
Nor Cough
(n = 207)
Fever AND Cough
(n = 214)
Neither Fever NOR
Cough NOR Myalgia
(n = 157)
Fever AND Cough
AND Myalgia
(n = 132)
ent Departments of the University Hospital Basel
during the study period (table 4). The highest
prevalence was among the patients tested in the
ICU: Two of seven suspected cases (29%) tested
positive.The total number of patients tested in all
Departments other than the ED was 57. Six pa-
tients were tested positive (table 4). Among the 51
patients tested negative, 16 suffered from bacterial
pneumonia (of which one Legionella and one
Mycoplasma could be identified), seven suffered
from bronchitis, asthma, or COPD, seven from
abdominal sepsis, five from other infections (of
which one HIV and one osteomyelitis), four from
cancer, and another four from different immuno-
logical causes. Of the remaining eight, five were
newborn infants and three were their mothers in
fear of an influenza infection.
Discussion
We report on a case series of patients with flu-
like symptoms during the first wave of the A/
H1N1v pandemic in Northwest Switzerland.
Consistent to previous reports, our population
had a median age of 32 years, possibly due to the
fact that younger adults are exposed to the virus
first, since they are the most active travelling pop-
ulation. In contrast, media coverage seemed to
heighten insecurity about morbidity and mortality
of this illness, especially in younger adults. Inter-
estingly, as the prevalence of the disease in patients
presenting with flu-like symptoms dropped in late
July, the number of presentations sharply in-
creased in August. Therefore, it could be debated
that the first wave of the pandemic was rather me-
dia-“hype” than real threat, especially when con-
sidering that the low prevalence of 5% dropped
even lower in August 2009 (figure 2).
As all patients were triaged according to the
ESI, and ESI 5 patients were not even triaged to
the flu clinic, other viruses must have been respon-
sible for the flu-like symptoms in the vast majority
of these patients. A previous, smaller study in
Northwestern Switzerland from this summer
detected respiratory viruses in 65% of the pa-
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tients, with the three leading pathogens being rhi-
noviruses in 36%, followed by adenovirus in 6%,
and human metapneumovirus in 5% [15]. In the
present study, the prevalence of A/H1N1v infec-
tion in the high risk group was also very low (4%).
Of note, no patient older than 50 years was tested
A/H1N1v-positive.
This low prevalence raises two questions: the
first addresses PCR testing strategies during the
first wave of a pandemic, especially when a media-
“hype” is driving hundreds of patients to their
family physicians, hospitals, or even EDs. For ex-
ample, cost-efficiency should be considered; as in
our cohort, the cost for PCR testing amounted to
$ 2483 per case identified.
In a disease in which, according to the last up-
date of the WHO from October 16, 2009, the
overwhelming majority of patients continue to ex-
perience an uncomplicated course, and in an envi-
ronment where the prevalence is only 5%, testing
should possibly be restrained to patients with
certain presentations, such as the combination of
fever, cough, and myalgia (see figure 1). However,
there is rising concern on the clinical course and
management of a small subgroup that rapidly de-
velops very severe progressive pneumonia, which
is often associated with organ failure, or a worsen-
ing of underlying pulmonary disease [16].Of note,
two patients with a severe course were not admit-
ted via the flu clinic, but were transferred to
our ICU. As of now, one patient is still being
treated by extracorporeal membrane oxygenation
(ECMO) due to respiratory failure. A second pa-
tient has been taken off the ECMO and is in a sta-
ble condition. This raises the second question
about the usefulness of flu clinics in low-preva-
lence areas or in decreasing prevalence. The cost
of human resources for our flu clinic during the
study period per case identified amounted to
$ 6900, with the vast majority of infected patients
leaving the ED untreated. For the cost of identify-
ing a single A/H1N1v-positive patient in our flu
clinic, 188 patients could have been treated with
Oseltamivir.
Limitations
Since this study was performed at a single ur-
ban tertiary care centre serving Northwestern
Switzerland, the generalisability of the results to
other communities is limited. One issue was that
the range of interpretation of the criteria given by
the BAG for testing was rather broad, leading to
over 500 tests in a city of 180000 inhabitants in a
period of 144 days. This liberal practice may not
be representative for Switzerland and Europe and
may lead to a bias in the interpretation of the data.
However, there were no other flu clinics in
Northwestern Switzerland (population >500000),
so a concentration of patients with flu-like symp-
toms can be expected. Secondly, there was no fol-
low-up on the population seen. As the only public
hospital in the city of Basel is the University Hos-
pital, it would be highly likely that patients with
clinical deteriorations occurring later would have
been hospitalized and retested by the same institu-
tion that they initially presented to.A possible bias
in favour of underreported hospitalisation there-
fore seems unlikely. Thirdly, as not every patient
was PCR-tested, the real prevalence of A/H1N1v
could be biased. This possible bias, however,
would most probably not have increased the
prevalence, but rather decreased, because testing
would rather be omitted in less severely sympto-
matic patients. Finally, we followed the recom-
mendation of the BAG to omit testing in the less
severely ill patients after August 3 (except for the
random sample of the first five patients each day),
possibly explaining the lower prevalence of posi-
tive tests for A/H1N1v in the second part of the
study period.
Conclusions
At present, it seems that the first wave of A/
H1N1v in Switzerland was rather media “hype”
than real threat. However, it remains to be ob-
served, whether the virus will mutate into a more
virulent or dangerous form, perhaps as early as of
now [17]. Thus, careful monitoring of A/H1N1v
infection during the upcoming winter season is of
critical importance to detect more virulent virus
variants. Also, historically, the second wave of an
influenza pandemic is usually more severe than
the first wave.
In conclusion, our data suggest that testing
Figure 2
Epidemiology of patients presenting to the ED with ﬂu-like symptoms.
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Table 4
A/H1N1v-PCR-Positive Patients in the University Hospital of Basel.
No. Age: Median,
(IQR)
Female
Gender:
No. (%)
PCR
Performed:
No. (%)
A/H1N1v-
PCR +:
No. (%)
ED* 808 32 (24, 42) 419 (52) 521 (65) 43 (5)
Medical Ward 23 55 (35; 68) 12 (52) 20 (87) 2 (9)
Obstetrics
$
16 30 (0; 37) 12 (75) 16 (100) 1 (6)
ICU
#
7 45 (39; 65) 3 (43) 7 (100) 2 (29)
Others 11 32 (26; 56) 5 (46) 9 (82) 1 (9)
* Emergency Department;
#
Intensive Care Unit;
$
including 5 newborn infants
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could be restricted to patients with more severe
symptoms, such as fever, coughing, and myalgia, in
order to save resources for later stages of the
present pandemic.
We are indebted to all physicians of our flu clinic,
as well as Didier Guy Voegelin from the Department of
Informatics for technical help and continuous support
throughout the study.We also thank Heinz Schuhmacher
from the Department of Infectious Diseases for prospec-
tively gathering patient- and A/H1N1v-PCR data.
Correspondence:
Roland Bingisser, MD, FCCP
Department of Emergency Medicine
University Hospital Basel
Petersgraben 2
CH-4031 Basel
Switzerland
E-Mail: BingisserR@uhbs.ch
References
1 Neumann G, Noda T, Kawaoka Y. Emergence and pandemic
potential of swine-origin H1N1 influenza virus. Nature. 2009;
459(7249):931–9.
2 Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van
Kerkhove MD, Hollingsworth TD, et al. Pandemic potential
of a strain of influenza A (H1N1): early findings. Science. 2009;
324(5934):1557–61.
3 Smith GJ,Vijaykrishna D, Bahl J, Lycett SJ,Worobey M, Pybus
OG,et al.Origins and evolutionary genomics of the 2009 swine-
origin H1N1 influenza A epidemic. Nature. 2009;459(7250):
1122–5.
4 BrankstonG,GittermanL,HirjiZ,LemieuxC,GardamM.Trans-
missionof influenzaA inhumanbeings.Lancet InfectDis.2007;7
(4):257–65.
5 Yang Y, Sugimoto JD,HalloranME, Basta NE,Chao DL,Mat-
rajt L, et al. The Transmissibility and Control of Pandemic In-
fluenza A (H1N1) Virus. Science 2009.
6 Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE,
Cummings DA. Incubation periods of acute respiratory viral in-
fections: a systematic review. Lancet Infect Dis. 2009;9 (5):291–
300.
7 Jamieson DJ, Honein MA, Rasmussen SA,Williams JL, Swer-
dlow DL, Biggerstaff MS, et al. H1N1 2009 influenza vi-
rus infection during pregnancy in the USA. Lancet. 2009;374
(9688):451–8.
8 Gordon CL, Johnson PDR, Permezel M, Holmes N, Gut-
teridge G, McDonald C, et al. Association between Severe
Swine-origin Influenza A Virus (S-OIV) Infection and Immu-
noglobulin G2 Subclass Deficiency. Book of Abstracts ICCAC/
49th Interscience Conference on Antimicrobial Agents and
Chemotherapy, September 12–15, 2009, San Francisco, CA.
2009. V-1269a
9 Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten
RJ et al. Emergence of a novel swine-origin influenzaA (H1N1)
virus in humans. N Engl J Med. 2009;360(25):2605–15.
10 Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR,
Louie J, et al. Hospitalized Patients with 2009 H1N1 Influenza
in the United States,April-June 2009.N Engl J Med. 2009.Oct
8. [Epub ahead of print]
11 Davies A, Jones D, Bailey M, Beca J, Bellomo R, Blackwell N,
et al. Extracorporeal Membrane Oxygenation for 2009 Influ-
enza A(H1N1) Acute Respiratory Distress Syndrome. JAMA.
2009;302(17):1888–95.
12 Goodwin R, Haque S, Neto F, Myers LB. Initial psychological
responses to Influenza A,H1N1 (“Swine flu”). BMC Infect Dis.
2009;9:166.
13 http://www.notfallstandards.ch.
14 Richt JA,LagerKM,ClouserDF,SpackmanE,SuarezDL,Yoon
KJ. Real-time reverse transcription-polymerase chain reaction
assays for the detection and differentiation of North Ameri-
can swine influenza viruses. J Vet Diagn Invest. 2004;16(5):
367–73.
15 Dumoulin A, Widmer AF, Hirsch HH. Comprehensive diag-
nostics for respiratory virus infections after transplantation or
after potential exposure to swine flu A/H1N1: what else is out
there? Transpl Infect Dis. 2009;11(4):287–9.
16 WHO. http://www.who.int/csr/disease/swineflu/en/.
17 Watson R. Swine flu could come back in more virulent form
after summer, European experts say. BMJ. 2009;338:b1792.
